London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Nice £44K buy late yesterday.
Thanks for that aim. Just to summarise the figures mentioned in his video, which were highlighted to justin via email by the nufornix ceo dan gooding....
Tecfidera bought for a fee of 510 million dollars (for a partial buy in!) and a later fee of 761 million dollars. Rhofade was acquired for 275 million dollars.
Huge figures and a big call to highlight out licensing deals of this magnitude. But dan has continually mentioned he wants to emulate what has happened with tecfidera in his interviews. Hes never highlighted figures until now. So i guess he must be confident of achieving something near to these.
Good video update there by Justin on V ox mark ets
It explains in a good way just how big this is going to be. A lot of news is building up here so imo this will move up sharply soon.
First chinese payment within days apparently but will they issue an rns? Doubt it, they didnt bother with first upfront ebers payment. Unless its going to get paired with an update on 002. I thought for a good while its nice to update progress on 002 , maybe trials to start at a certain date paired with an update on money received from china.
Just topped up. You think we'll get the Chinese payment this week?
However, it would be helpful if the CEO did not talk of things like possible need for funding in the future which can be misconstrued. Desperate need for broker.
int posts.. as regards any delays over NSB/Yatai.. These could be for many reasons knowing the chinese. The data in English, tested by UK bodies. Patents that were issued to NSB before the takeover . Chinese wanting to tie in other deals. It could be one of many different things..
What we can say. If there was anything that effected the deal or the payments that was negative. The company is duty bound to inform the market.
Therefore there is nothing wrong.
who knows if it is not another curve ball..
Many investors seem to forget the amazing results we just achieved NXP001.
Let alone last returns confirms patents and milestones from Ebers look to be incoming.. These if large will help fund the 002 with our low cost model ..
exciting times ahead.. esp NXP002 ..
You only have to look at the Ebers deal to see potential values if they sourced subject to development £51 million on that excluding the 20% royalties which is great then a value of just £300 million very small target near term on NXP001 multiple leads and one secured in a 2.5 billion market alone annually then NXP002 in a many multiples size market and add further leads plus other molecules not excluding NXP003 ongoing and more collaborations one to be held very tight to the chest which awaits to be released.
I've recently bought in here and was also intrigued by Dan's vision.
I was quite pleased when he brought up the exit strategy but I wouldn't (personally) see them selling the company for £0.25 billion (50p per share). If as he intimated in the interview to have "several programs" developed to P2A or P2B with patents, he will be looking for I would expect minimum £2bn +, obviously depending on the competition (usually target unmet need as in Fibrosis) efficacy, market potential reach negotiated percentages, competition etc. I think he knows full well the value of the company when he cited Biogen and the other product. He is probably looking 2-3 years ahead to get several programs to that point and the share price should be more reflective of the potential. All IMHO, but very pleased to be holding a stock such as this where much of the technology is proven. It seems locating the more lucrative molecules and getting in ahead of competition is the biggest challenge.
Yes, I noticed that too, Storm, though have heard him talk about before too. Hopefully we'll see some good progress on the licensing of 001, some newsflow updating on progress on the 002 Fibrosis drug and at some point 'beyond 002' news too. Commercialing 001 should add significant value but get the impression that the Fibrosis drug could be the blockbuster one in terms of value. Assuming the co-crystal success is replicated with 002 you'd think a big Pharma would see it as a license to print money, buy it and scale it up? Remains great share to be in, IMO.
If you are referring to the latest Vox Markets interview with Anita Riotta(sp?) then was a most revealing quick aside that the interviewer failed to pick up on.
Dan mentioned the words 'exit strategy'.
Since Dan has now opened this subject it is really important that investors are able to understand the details of this envisaged exit strategy - timing, target price and so on.
I was hoping for £2 + a share, but if we are going to get sold out at 50p or something silly like that, then it will be a great shame.
Appreciated Dan doing the video the other week. Whilst he couldn't give much away, it keeps nfx front of mind, and good he recognises investor comms is something to focus on moving forwards. I'm just sitting tight and playing the long game here. It surely cant be too long now til spreadex clear and the downward selling pressure is gone. And with the licensing work going on in the background I just dont feel like it's a share I want to risk being out of when the good news does land. Dan is always coy about target valuations but when he does drop a hint about comparable stories, if you look them up we're talking many multiples of where we are now and that's just for ONE drug.
Positive news that former Vectura Ceo is joining the board. More exciting prospects here perhaps. Hopefully shares will be back above 10p soon.........clear upward resistance there now so short term share weakness cannot therefore be ruled out IMHO.
“Ongoing licensing and collaborative revenues are sufficient to fund further pipeline development in 2019 thereby maximising shareholder value.”
“"With significant income due from IP licensing and collaborative development programmes in H1 2019/20 and validation of its platform in clinic, we're very excited that Nuformix is positioned well to progress multiple programmes towards patients, delivering its promise of therapeutic innovation and growth in shareholder value."”
“ Combined income from the Newsummit Biopharma Licensing agreement for NXP001 and the Strategic Cannabinoid Agreement signed with Ebers is expected to generate significant income in H1 2019/20. The Group is in commercial discussions with a number of organisations regarding additional out-licensing and collaborative development opportunities which will also be revenue generating in 2019.”
Winnieh I think anyone could sit and be negative about any company. You have been consistently slanted that way here since 2017 and since then Dan has delivered time and time again. I can as you say state that the 2mil will be coming just like the 500k will be. To state it as @if” is purely gamesmanship by you to play and be and antagonist here. You have done it all the way up. Really!!! Is it Really necessary for you to be here trying. WTFP??? You need to maybes look elsewhere if you find it so difficult here lol. The facts are all in this statement by the company and it is going to be exceptionally valuable news dropping H1.
“The validation in clinic established for our underlying technology, the subsequent de-risking of Nuformix's wider pipeline and the completion of the Ebers deal confirm our business model is working to deliver significant growth in shareholder value in 2019/2020.”
everything is guess work,i hope we do get a curve ball,i hope the chinese give us 10m,until then good luck mars.but dan did say he will give us more news updates,which is a good result,all the best
trust me its a struggle.next news 500k,then broker.NOT 2m
and what happened at the meeting with liberum and the round table
Not a struggle just a group reallocation of the contract to the parent company.
we are struggling to get 2m off the chinese let alone 10m royalties
PS this is how a typical co is valued and shows on historic terms this co is already undervalued. This co is not typical and should not be valued in this way there is no concept here of what this co is capable.
The first set of figures are from the accounts and confirmed in RNS’s. The eg after with a conservative £10m shows the effect of having a low cost model on the relation of revenue to price. Everything goes to the bottom line costs remain relatively static. £10m is not demanding.
where do you get them figures,please,you cant just pluck figures out of thin air,i hope your right but where just where.10m royalties,never saw that in final results or podcast
If a simple extrapolation is done and say £10m royalties are received with running costs of £1.5m gives £8.5m at a p/e of 20 gives a value of £170m more than 4 times current value does not take much for this share price to escalate. This has stratospheric possibilities!!
Just had another look. Annual costs included exceptional items of just under £1m one off items to do with the reverse takeover . Makes numbers for 2020 even better. Running costs are £1.5m per annum with revenue Ytd so far of £3.4m with more to come. Take a pe of 20 (May be understated given royalty income) on current numbers gives a value of £38m. On current NAV only leaves a £3m balance for everything else bargain for new investors probably.